I have posted about this before--the papers seem to come out of Oregon. At SABCS in 2005 I discuss this with one of the authors at a poster session
Breast Cancer Res Treat. 2008 Aug 20. [Epub ahead of print]
Vitreo-retinal traction and anastrozole use.
Eisner A, Thielman EJ, Falardeau J, Vetto JT.
Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwilliger Blvd, 97239, Portland, OR, USA,
eisnera@ohsu.edu.
Purpose This study tested a prediction stemming from the hypothesis that anastrozole users experience heightened vitreo-retinal traction. This hypothesis was based on the knowledge that menopause increases the risk of intraocular tractional events such as posterior vitreous detachments (PVDs). Methods Retinal thickness was measured for 3 groups of amenorrheic women: (1) anastrozole users and (2) tamoxifen users undergoing adjuvant therapy for early-stage breast cancer, and (3) control subjects not using hormonal medication. Foveal shape indices were derived for subjects without PVDs. Results For anastrozole users, the distance to the temporal side of the fovea became less than the distance to the nasal side at a sufficient height above the foveal base. This effect did not exist for control subjects; the between-group difference was appreciable. Results concerning tamoxifen users were inconclusive. Conclusions The foveas of women using anastrozole appear to be subjected to more tractional force than are the foveas of women not using any hormonal medication.
PMID: 18712596 [PubMed - as supplied by publisher]
Related Articles
Retinal hemorrhages in anastrozole users.
[Optom Vis Sci. 2008]
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
[Breast Cancer Res Treat. 2007]
Linear Mode
